Project Description
Initial Public Offering
Common Stock
$28,347,500
Co-Manager
October 2013
ADMA Biologics
dan2023-12-14T22:35:41-05:00
ADMA Biologics
dan2023-12-14T22:35:41-05:00
ADMA Biologics
dan2023-12-14T22:35:41-05:00
ADMA Biologics
dan2023-12-14T22:35:41-05:00
Site Info
Contact Info
© 2024 Copyright Laidlaw & Company (UK) Ltd. – All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through StoneX, a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).
© Copyright 2013 Laidlaw & Company (UK) Ltd. - All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through INTL FCStone Financial Inc., a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).
Stay In Touch